Mr John Robinson Knox Jr, DO | |
12605 E 16th Ave, Aurora, CO 80045-2545 | |
(720) 848-0000 | |
Not Available |
Full Name | Mr John Robinson Knox Jr |
---|---|
Gender | Male |
Speciality | Psychiatry |
Experience | 9 Years |
Location | 12605 E 16th Ave, Aurora, Colorado |
Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1669507000 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
2084P0800X | Psychiatry & Neurology - Psychiatry | 6008 (Oklahoma) | Secondary |
2084P0800X | Psychiatry & Neurology - Psychiatry | DR.0061805 (Colorado) | Primary |
Group Practice Name | Group PECOS PAC ID | No. of Members |
---|---|---|
Southern California Permanente Medical Group | 6002729175 | 7951 |
News Archive
BIOLASE Technology, Inc., the world's leading dental laser company, today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market its Waterlase MD™ laser system for removal of subgingival calculi to prevent and treat periodontitis, the greatest cause of tooth loss for adults over 35 and a condition impacting more than half of Americans over the age of 55, as reported by the American Academy of Periodontology (AAP).
CSC, a global leader in technology-enabled solutions and services, and Cordys, a leading provider of software for business process innovation, today announced a strategic alliance.
Neuland Laboratories Ltd., a pharmaceutical manufacturer providing active pharmaceutical ingredients, complex intermediates and contract manufacturing services to customers located in 85 countries, today announced financial results for the first quarter of fiscal year 2014, ended June 30, 2013.
Researchers from the University of Birmingham have found that extended rest intervals between sets of weight-lifting could help with muscle growth.
Forest Laboratories, Inc. (NYSE: FRX) and Glenmark Pharmaceuticals S.A. (Switzerland), a wholly owned subsidiary of Glenmark Pharmaceuticals India (GPL) today announced top-line results from a Phase IIb dose range-finding study of oglemilast in patients with Chronic Obstructive Pulmonary Disease (COPD). Once-daily treatment with oglemilast did not show a statistically meaningful increase from baseline compared to placebo in the primary endpoint trough FEV1, a measure of pulmonary function that is decreased in patients with COPD. Oglemilast was well tolerated at all doses studied.
› Verified 8 days ago
Entity Name | Southern California Permanente Medical Group |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1770515280 PECOS PAC ID: 6002729175 Enrollment ID: O20031110000678 |
News Archive
BIOLASE Technology, Inc., the world's leading dental laser company, today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market its Waterlase MD™ laser system for removal of subgingival calculi to prevent and treat periodontitis, the greatest cause of tooth loss for adults over 35 and a condition impacting more than half of Americans over the age of 55, as reported by the American Academy of Periodontology (AAP).
CSC, a global leader in technology-enabled solutions and services, and Cordys, a leading provider of software for business process innovation, today announced a strategic alliance.
Neuland Laboratories Ltd., a pharmaceutical manufacturer providing active pharmaceutical ingredients, complex intermediates and contract manufacturing services to customers located in 85 countries, today announced financial results for the first quarter of fiscal year 2014, ended June 30, 2013.
Researchers from the University of Birmingham have found that extended rest intervals between sets of weight-lifting could help with muscle growth.
Forest Laboratories, Inc. (NYSE: FRX) and Glenmark Pharmaceuticals S.A. (Switzerland), a wholly owned subsidiary of Glenmark Pharmaceuticals India (GPL) today announced top-line results from a Phase IIb dose range-finding study of oglemilast in patients with Chronic Obstructive Pulmonary Disease (COPD). Once-daily treatment with oglemilast did not show a statistically meaningful increase from baseline compared to placebo in the primary endpoint trough FEV1, a measure of pulmonary function that is decreased in patients with COPD. Oglemilast was well tolerated at all doses studied.
› Verified 8 days ago
Mailing Address | Practice Location Address |
---|---|
Mr John Robinson Knox Jr, DO Po Box 110429, Aurora, CO 80042-0429 Ph: () - | Mr John Robinson Knox Jr, DO 12605 E 16th Ave, Aurora, CO 80045-2545 Ph: (720) 848-0000 |
News Archive
BIOLASE Technology, Inc., the world's leading dental laser company, today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market its Waterlase MD™ laser system for removal of subgingival calculi to prevent and treat periodontitis, the greatest cause of tooth loss for adults over 35 and a condition impacting more than half of Americans over the age of 55, as reported by the American Academy of Periodontology (AAP).
CSC, a global leader in technology-enabled solutions and services, and Cordys, a leading provider of software for business process innovation, today announced a strategic alliance.
Neuland Laboratories Ltd., a pharmaceutical manufacturer providing active pharmaceutical ingredients, complex intermediates and contract manufacturing services to customers located in 85 countries, today announced financial results for the first quarter of fiscal year 2014, ended June 30, 2013.
Researchers from the University of Birmingham have found that extended rest intervals between sets of weight-lifting could help with muscle growth.
Forest Laboratories, Inc. (NYSE: FRX) and Glenmark Pharmaceuticals S.A. (Switzerland), a wholly owned subsidiary of Glenmark Pharmaceuticals India (GPL) today announced top-line results from a Phase IIb dose range-finding study of oglemilast in patients with Chronic Obstructive Pulmonary Disease (COPD). Once-daily treatment with oglemilast did not show a statistically meaningful increase from baseline compared to placebo in the primary endpoint trough FEV1, a measure of pulmonary function that is decreased in patients with COPD. Oglemilast was well tolerated at all doses studied.
› Verified 8 days ago
Lea C Watson, MD Psychiatry & Neurology Medicare: Medicare Enrolled Practice Location: 1890 N Revere Ct, Aurora, CO 80045 Phone: 720-848-0000 | |
Robert House, MD Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 12605 E 16th Ave, Aurora, CO 80045 Phone: 720-848-0000 | |
Ann Olincy, MD Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 12605 E 16th Ave, Aurora, CO 80045 Phone: 720-848-0000 | |
Paul Moe, MD Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 13123 E 16th Ave, Aurora, CO 80045 Phone: 720-777-1234 | |
Dr. Erin Schwarz, D.O. Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 1537 Alton St, Aurora, CO 80010 Phone: 303-617-2300 | |
Robert Clyman, MD Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 13123 E 16th Ave, Aurora, CO 80045 Phone: 720-777-1234 | |
Dr. Bishara Bhasi, MD Psychiatry & Neurology Medicare: Medicare Enrolled Practice Location: 13123 E 16th Ave, Aurora, CO 80045 Phone: 720-848-0000 |